Unit 5: Approach to Syncope & Miscellaneous Ischemia

Sign-up for Instructor Access

References

  1. Sieira J, Brugada P. The definition of the Brugada syndrome. Eur Heart J. 2017;38(40):3029-3034. doi:10.1093/eurheartj/ehx490
  2. Sharifi M, Bay C, Skrocki L, Rahimi F, Mehdipour M. Moderate pulmonary embolism treated with thrombolysis (from the “mOPETT” Trial). Am J Cardiol. 2013;111(2):273-277. doi:10.1016/j.amjcard.2012.09.027
  3. Kline JA, Nordenholz KE, Courtney DM, et al. Treatment of submassive pulmonary embolism with tenecteplase or placebo: Cardiopulmonary outcomes at 3 months: Multicenter double-blind, placebo-controlled randomized trial. J Thromb Haemost. 2014;12(4):459-468. doi:10.1111/jth.12521
  4. Meyer G, Vicaut E, Danays T, et al. Fibrinolysis for Patients with Intermediate- Risk Pulmonary Embolism. N Engl J Med. 2014;370(15):1402-1411. doi:10.1056/NEJMoa1302097
  5. Sharifi M, Vajo Z, Javadpoor S, et al. Pulseless electrical activity in pulmonary embolism treated with thrombolysis (from the “PEAPETT” study). Am J Emerg Med. 2016;34(10):1963-1967. doi:10.1016/j.ajem.2016.06.094
  6. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Vol 72.; 2018. doi:10.1161/CIR.0000000000000549
  7. Isbister GK. Risk assessment of drug-induced QT prolongation. Aust Prescr. 2015;38(1):20-24. doi:10.18773/austprescr.2015.003